æ°åã³ãããŠã€ã«ã¹SARS-CoV-2ã«å¯ŸããDNAã¯ã¯ãã³ãéçºããŠãããã€ãªãã³ãã£ãŒããã以å€ã«ãã¢ãã¯ããŒãã«æäœãã³ãŒãããDNAå»è¬åæè¡dMAbâ¢ãšããç¬èªæè¡ãæã€ãããã¯ã¯ãã³ã®èšåºéçºãã
ããŒã ããŒãžïŒhttps://www.inovio.com/
èæ¯ãšãã¯ãããžãŒïŒ
ã»æ°åã³ãããŠã€ã«ã¹ææçCOVID-19ã®æ²»çè¬ãšããŠGileadã®ã¬ã ãã·ãã«ãFDAããç·æ¥äœ¿çšèš±å¯ãååŸããïŒ2020幎5æ2æ¥ïŒãããã¯ç±³åœå±äž»å°ã®èšåºè©Šéšã«ãããŠãå埩ã«ããã£ãæéãã¬ã ãã·ãã«ã®éèå æäžãåããæ£è ã§å¹³å11æ¥ã ã£ãã®ã«å¯Ÿãããã©ã»ã矀ã§ã¯15æ¥ã ã£ãããšã«ããïŒåèïŒã
ã»ãã®åŸãéçæ£è ã«å¯Ÿããã¬ã ãã·ãã«ã®æå¹æ§ã5æ¥æäžãš10æ¥æäžã§æ¯èŒãããšãããå·®ããªãã£ããšããå ±åã¯ãã£ãïŒåèïŒããä»ã®ãšãããã¬ã ãã·ãã«ã¯å埩æéã®ç瞮以å€ã®å¹æïŒæ»äº¡çäœäžãªã©ïŒã®å ±åã¯ãªãã
ã»ãããã®çµæãããæ°åã³ãããŠã€ã«ã¹ææçã«ã¯ã¬ã ãã·ãã«ã ãã§ã¯ååãšã¯èšãããæ°ããªæ²»çè¬ãå¿ èŠãšãããŠãããVir Biotechnologyã¯ãSARS-CoV-2ã®ã¹ãã€ã¯ããã±ã質ãèªèããäžåã¢ãã¯ããŒãã«æäœVIR-7831ãVIR-7832ãéçºããŠããã
ã»æ°åã³ãããŠã€ã«ã¹ã®ãã³ãããã¯ã解決ããããã«ã¯ãäžèšã®æ²»çè¬ã ãã§ã¯ãªããã¯ã¯ãã³ã®éçºãå¿ èŠã§ãããæ²»çè¬ã¯æ°åã³ãããŠã€ã«ã¹ã«ææãã人ãå埩ããããã«å¿ èŠãšãªãããææãåºãŸãããšãæããå¹æã¯äœãããã§ãããææãåºãŸãããšãæããã«ã¯ãå¥åº·ãªäººãæ°åã³ãããŠã€ã«ã¹ã«ææããããšãæå¶ããããšãå¿ èŠã§ãããã«ã¯ã¯ã¯ãã³ãéçºããå¿ èŠãããã
ã»æ°åã³ãããŠã€ã«ã¹SARS-CoV-2ã«å¯Ÿããã¯ã¯ãã³éçºã®ã¢ãããŒããšããŠã©ããªãã®ãããã®ãã¯ãMedicagoã玹ä»ããããã°ã«èšèŒããïŒãã¡ãïŒãäžçã®ã¯ã¯ãã³ç«¶äºã¯ãmRNAã¯ã¯ãã³ãéçºããŠããModernaãBioNTechãã¢ãããŠã€ã«ã¹ãã¯ã¿ãŒã¯ã¯ãã³ãéçºããŠããCanSino Biologicsãªã©ãå è¡ããŠããããå¹æãæã€ã¯ã¯ãã³ãäœãã®ã¯ç°¡åã§ã¯ãªãå¯èœæ§ããããããã¯HIVïŒAIDSã®ãŠã€ã«ã¹ïŒã¯ã¯ãã³ãæªã ã«å®æããŠããªãããšããããã®å¯èœæ§ãæšæž¬ããããmRNAã¯ã¯ãã³ãã¢ãããŠã€ã«ã¹ãã¯ã¿ãŒã¯ã¯ãã³ãå¿ ãããããŸããããšã¯éããªãããããã以å€ã®ã¢ãããŒããé²ããŠããå¿ èŠãããã
ã»ä»å玹ä»ããINOVIOã¯æ°åã³ãããŠã€ã«ã¹SARS-CoV-2ã«å¯ŸããDNAã¯ã¯ãã³ã®éçºãè¡ã£ãŠãããã€ãªãã³ãã£ãŒã§ãããããããããŒããŠã€ã«ã¹ïŒHPVïŒãããããææçã«å¯ŸããDNAå»è¬åã®éçºãè¡ã£ãŠããã
ã»INOVIOã§ã¯ä»¥äžã®ç¬èªæè¡ãéçºããŠãã
â æ£ç¢ºã«ãã¶ã€ã³ããããã©ã¹ããïŒSynCon®ïŒ
INOVIOã®DNAå»è¬åã¯SynCon®ãšããããã»ã¹ã«ãã£ãŠäœããããSynCon®ã§ã¯ãæšçæåã®DNAé åãåå®ãæé©åããããã®ç¬èªã®ã³ã³ãã¥ãŒã¿ãŒã¢ã«ãŽãªãºã ã䜿ã£ãŠããã
â¡ç¬èªã®ã¹ããŒãããã€ã¹ïŒCELLECTRA®ïŒ
DNAå»è¬åïŒãã©ã¹ããïŒã¯çèå ãããã¯ç®å ã«æäžããããæäžã«ã¯æºåž¯åïŒæã§æã£ãŠæäœã§ããïŒCELLECTRA®ãšããç¬èªã®ã¹ããŒãããã€ã¹ãçšãããCELLECTRA®ã¯çæéã®é»æ°ãã«ã¹ãçºçãããããšã§ãå¯éçã«çŽ°èã«å°ããªç©Žãéãããã©ã¹ããã现èå ïŒæ žå ïŒã«å ¥ãããã«ããããã®ããã€ã¹ã§ããã
ã»CELLECTRA®ã§çèå ãããã¯ç®å ã«æäžããããã©ã¹ããã¯ã现èå ã«å ¥ããšæšçæåãçºçŸããT现èæ§å ç«ãæäœã«ããå ç«åå¿ãæ¹èµ·ããã
ã»DNAã¯ã¯ãã³ã®å©ç¹ãæ¬ ç¹ã¯ä»¥äžã®éãïŒMedicagoã®èæ¯ãšãã¯ãããžãŒæ¬ãã転èšïŒã
DNAã¯çŽ°èæ žãŸã§å°éãããå¿ èŠãããïŒRNAã¯çŽ°èèãééããŠçŽ°è質ãŸã§å°éããã°çºçŸããïŒãå®å®æ§ãéºäŒåå°å ¥å¹çãäžããããã«è質ããç²åãªã©ã«å°å ¥ããã±ãŒã¹ãèããããã
ã¡ãªãããçç©è£œå€ã§ã¯ãªãããã«è£œé ã簡䟿ã§å€§é補é ããããïŒãã ãæ¿èªæžã¿ã¯ã¯ãã³ããªãããèªå¯æžã¿è£œé æœèšããŸã ãªãïŒãç 究ã補é ã茞éãä¿åãæäžæã«ç åæ§ãŠã€ã«ã¹ãæ±ãå¿ èŠããªããåžžæž©ä¿åå¯èœã
ãã¡ãªãããã¯ã¯ãã³ã®å ç«å¹æã®ããã«ç¹æ®ãªæäžããã€ã¹ãå¿ èŠãšãªãã
ã»INOVIOã§ã¯DNAã«ãã£ãŠçºçŸãããã¢ãã¯ããŒãã«æäœïŒdMAbâ¢)ãšããç¬èªæè¡ãæã€ãæäœå»è¬åã¯è£œé ã«éåžžã«ã³ã¹ãããããããDNAå»è¬åã®åœ¢ã§ããã°ã³ã¹ããæžããããšãã§ãããdMAbâ¢ã¯ãç¹å®ã®ã¢ãã¯ããŒãã«æäœã®DNAé åãã³ãŒããããã©ã¹ããDNAãäžèšã®CELLECTRA®ããã€ã¹ãçšããŠæäžããæè¡ã§ãããããã«ãããã¢ãã¯ããŒãã«æäœãããã®äœå ã§çç£ããããã¢ãã¯ããŒãã«æäœä»¥å€ã«ã2éç¹ç°æ§T现èãšã³ã²ãŒãžã£ãŒïŒBiTEsïŒãªã©ã«ãå¿çšå¯èœã§ããã
ãã€ãã©ã€ã³ïŒ
ã»VGX-3100
åå®®é žãããåŒãèµ·ãããªã¹ã¯ãç¹ã«é«ãããããããŒããŠã€ã«ã¹HPV16ãHPV18ã®E6/E7éºäŒåãã³ãŒããããã©ã¹ããDNAãäžåœã«ãããéçºã¯äžåœApollobioãšã®å ±åéçºã
éçºäžã®é©å¿ç
ã»Phase II/III
ã»MEDI0457
åå®®é žãããåŒãèµ·ãããªã¹ã¯ãç¹ã«é«ãããããããŒããŠã€ã«ã¹HPV16ãHPV18ã®E6/E7éºäŒåãã³ãŒããããã©ã¹ããDNAãAstraZenecaãšã®å ±åéçºã
éçºäžã®é©å¿ç
ã»Phase I/II
é é žéšãã
ã»INO-3107
å°åã³ã³ãžããŒãã®90%以äžã®åå ãšãªã£ãŠããHPV6ãHPV11ã®E6/E7éºäŒåãã³ãŒããããã©ã¹ããDNAã
éçºäžã®é©å¿ç
ã»Phase I/II
ã»INO-5401
WT1ãPSMAãhTERTãã³ãŒããããã©ã¹ããDNAãREGENERONãšã®å ±åéçºã
éçºäžã®é©å¿ç
ã»Phase II
ã»INO-5151
PSAãPSMAãã³ãŒããããã©ã¹ããDNAã
éçºäžã®é©å¿ç
ã»Phase II
åç«è ºãã
ã»PENNVAX-GP
HIVãŠã€ã«ã¹ã®GagãpolãenvéºäŒåãã³ãŒããããã©ã¹ããDNAã
éçºäžã®é©å¿ç
ã»Phase I/II
HIVææ
ã»INO-4201
ãšãã©ãŠã€ã«ã¹ã®ç³ã¿ã³ãã¯è³ªéºäŒåãã³ãŒããããã©ã¹ããDNAã
éçºäžã®é©å¿ç
ã»Phase I
ãšãã©ãŠã€ã«ã¹ææç
ã»INO-4700ïŒGLS5300ïŒ
MERSïŒäžæ±åŒåžåšçå矀ïŒã³ãããŠã€ã«ã¹ã®ã¹ãã€ã¯ããã±ã質ãã³ãŒããããã©ã¹ããDNAã
éçºäžã®é©å¿ç
ã»Phase II
MERSã³ãããŠã€ã«ã¹ææ
ã»INO-4600ïŒGLS5700ïŒ
ZikaãŠã€ã«ã¹ã®ç³ã¿ã³ãã¯è³ªéºäŒåãã³ãŒããããã©ã¹ããDNAã
éçºäžã®é©å¿ç
ã»Phase I
ZakaãŠã€ã«ã¹ææ
ã»INO-4500
ã©ããµãŠã€ã«ã¹ïŒã©ããµç±ãåŒãèµ·ãããŠã€ã«ã¹ïŒã®ç³ã¿ã³ãã¯è³ªéºäŒåãã³ãŒããããã©ã¹ããDNAã
éçºäžã®é©å¿ç
ã»Phase I
ã©ããµç±ææ
ã»INO-4800
æ°åã³ãããŠã€ã«ã¹SARS-CoV-2ã®ã¹ãã€ã¯ããã±ã質éºäŒåãã³ãŒããããã©ã¹ããDNAã
éçºäžã®é©å¿ç
ã»Phase I
æ°åã³ãããŠã€ã«ã¹SARS-CoV-2ææ
ã»INO-A002
ZikaãŠã€ã«ã¹ã®ç³ã¿ã³ãã¯è³ªãèªèããã¢ãã¯ããŒãã«æäœéºäŒåãã³ãŒããããã©ã¹ããDNAã
éçºäžã®é©å¿ç
ã»Phase I
ãžã«ç±
æè¿ã®ãã¥ãŒã¹ïŒ
æ°åã³ãããŠã€ã«ã¹SARS-CoV-2ã¯ã¯ãã³INO-4800ã®äžåœã«ãããèšåºéçºãäžåœAdvaccine Biotechnologyãšå ±åã§è¡ãå¥çŽãç· çµã
ã³ã¡ã³ãïŒ
ã»ã¯ã¯ãã³éçºããã°ã©ã ã®ãã¡ã®ããã€ãã«ãããŠãæšçæåãçºçŸãããã©ã¹ãããšäžç·ã«ãIL-12éºäŒåãã³ãŒããããã©ã¹ããINO-9012ãå ±æäžããŠãããããã«ããå ç«åå¿ãæ¹èµ·ããããšãç®çãšããŠããã
ã»DNAã¯ã¯ãã³ã¯mRNAã¯ã¯ãã³ã«æ¯ã¹ãŠå®å®æ§ã«åªãããããé·æã®äœæž©ä¿åãé£ããçºå±éäžåœãªã©ã«ãããŠãç¹ã«æå©ã«ãªããšæããããäžæ¹ã§ãDNAã¯çŽ°èæ žãŸã§å°å ¥ãããªããšéºäŒåçºçŸããªããããç¹æ®ãªããã€ã¹ïŒCELLECTRA®ïŒãçšããŠæäžããªããšãããªããšããæ¬ ç¹ãããããŸããDNAã¯mRNAã«æ¯ã¹ããšã²ãã ã«çµã¿èŸŒãŸãããªã¹ã¯ããããããããåã®å¯èœæ§ãªã©ã泚æããªããšãããªãã
ã»æ°åã³ãããŠã€ã«ã¹ã®Phase II以éã®æ²»éšã¯ã以äžã®ãããªèª²é¡ããã
â ææãè延ããŠããã¿ã€ãã³ã°ã§ãªããšéåžžã«æéããããïŒãããã¯çµã¿å ¥ã人æ°ãå¢ããå¿ èŠãããïŒã
â¡äžçäžã§ã¯ã¯ãã³éçºãé²ãäžã§ãæ²»éšåå è ïŒã¯ã¯ãã³ã®å Žåã¯å¥åžžäººïŒã®å¥ªãåããèµ·ãã£ãŠããã ããã
â¢æ¿åºããã®ãµããŒããåŸãããäŒç€Ÿã«ãšã£ãŠã¯æ²»éšãã¹ã ãŒãºã«é²ããããã以å€ã®äŒç€Ÿã«ãšã£ãŠã¯æ²»éšé²æã®èª²é¡ã«ãªãããã ã
ããŒã¯ãŒãïŒ
ã»DNAã¯ã¯ãã³
ã»æ°åã³ãããŠã€ã«ã¹ææçCOVID-19
ã»ããããããŒããŠã€ã«ã¹
ã»ãã
ã»ææç
å 責äºé ïŒ
æ£ç¢ºãªæ å ±æäŸãå¿ãããŠããŸãããæ¬å 容ã«åºã¥ããåŠäœãªãã¢ã¯ã·ã§ã³ã«å¯ŸããŠãçè ã¯è²¬ä»»ããšããŸããããããããé¡ãããŸãã